Special Issue

Therapeutic Strategies for Heart Failure

Message from the Guest Editors

With high mortality, morbidity, and socioeconomic burden, heart failure (HF) remains a major challenge but at the same time one of the most rapidly developing areas in modern cardiology. Recent years, and in fact weeks, have brought crucial advances in the treatment of both HF with reduced (HFrEF) and, for the first time, HF with preserved ejection fraction (HFpEF). In this Special Issue, we aim to focus on a broad range of therapeutic strategies in HF and would like to invite the submission of research articles, review papers, and case reports Dr. Agnieszka Kapłon-Cieślicka

Guest Editors

Dr. Agnieszka Kaplon-Cieslicka

1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1a, 02-097 Warsaw, Poland

Dr. Monika Gawałko

- Department of Cardiology, Maastricht University Medical Centre and Cardiovascular Research Institute Maastricht, Universiteitssingel 50, 6229 ER Maastricht, The Netherlands
- 2. Institute of Pharmacology, West German Heart and Vascular Centre, University Duisburg-Essen, Hufelandstraße 55, 45147 Essen, Germany 3. 1st Department of Cardiology, Medical University of Warsaw, Banacha 1A, 02-197 Warsaw, Poland

Deadline for manuscript submissions

closed (31 December 2022)



Journal of
Cardiovascular
Development and
Disease

an Open Access Journal by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/99392

Journal of Cardiovascular Development and Disease Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jcdd@mdpi.com

mdpi.com/journal/ jcdd





Journal of Cardiovascular Development and Disease

an Open Access Journal by MDPI

Impact Factor 2.3 CiteScore 3.7 Indexed in PubMed





Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (*JCDD*, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to *JCDD* undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. *JCDD* guarantees fast dissemination of results to a large scientific audience

Editor-in-Chief

Prof. Dr. Thomas Brand

National Heart & Lung Institute, Imperial College London, South Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) / CiteScore - Q2 (General Pharmacology, Toxicology and Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.8 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).

